Authors
Type of Series
Number in series
Endpoint Pretreatment variables Variables at biochemical failure
PSA at STI (
g/L) Other prognostic variables Gleason score Clinical stage TTBF years PSADT months Sandler et al. (2000) [5 ] Single hospital, radiotherapy, retrospective 154 Survival NS NS — Continuous — — D’Amico et al. (2002) [6 ] Single hospital, radiotherapy, retrospective 381 Survival — — NS ≤12 >10 — Moul (2003) [7 ]† Community database, prostatectomy 1352 Survival >7 — ≤1 ≤12 ≤5, ≤10 — Okotie et al. (2004) [8 ] Single hospital, prostatectomy, retrospective 126 Metastases — — — <6 — —
Stephenson et al. (2007) [9 ] Multihospital, prostatectomy and radiotherapy, retrospective 1540 PSA progression >7 Positive margins — ≤10 Continuous — Freedland et al. (2005) [10 ] Single hospital, prostatectomy, retrospective 379 Survival >7 — ≤3 <3 — — Dotan et al. (2005) [11 ] Single hospital, prostatectomy, retrospective 239 Bone metastases — — — Continuous Continuous —
Slovin et al. (2005) [12 ]
Single hospital, prostatectomy, retrospective 148 Metastases >7 ≥T3 — Continuous Continuous — Zhou et al. (2005) [13 ] Community databases, prostatectomy and radiotherapy, retrospective 1159 Survival >7 — NS <3 — — Tollefson et al. (2007) [14 ] Single hospital, prostatectomy, retrospective 1064 Survival (overall) metastases — — — <12 — — Buyyounouski et al. (2008) [15 ] Single hospital, radiotherapy, 248 Survival > 6 (metastases only) — <1.5 NS — PSA nadir <2
g/L (metastases only)
